This metabolite has a PDE selectivity profile much like sildenafil and an in vitro potency for PDE5 around 50% on the guardian drug. Plasma concentrations of this metabolite are about 40% of those noticed for sildenafil, so which the metabolite accounts for around 20% of sildenafil’s pharmacologic consequences.Increased side effects can contain l